Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Adobe's (ADBE) first-quarter fiscal 2023 results are expected to reflect gains from solid momentum across the Digital Media and Digital Experience segments.

Zacks Equity Research

Catalyst Pharmaceuticals, Inc. (CPRX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

JD.com (JD) to Release Q4 Earnings: What's in the Offing?

by Zacks Equity Research

JD.com's (JD) fourth-quarter results are likely to reflect strength across JD Retail and JD Logistics amid uncertainties related to the coronavirus pandemic.

Zacks Equity Research

Docebo (DCBO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Docebo's (DCBO) fourth-quarter performance is expected to have gained from steady demand for its enterprise learnings solutions boosted by an expanding client base.

Zacks Equity Research

MongoDB (MDB) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

MongoDB's (MDB) fourth-quarter fiscal 2023 results are expected to reflect the high retention rate and growth in direct sales customers.

Zacks Equity Research

Corcept's (CORT) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Corcept Therapeutics' (CORT) fourth-quarter earnings and revenues lag estimates.

Zacks Equity Research

Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall

by Zacks Equity Research

Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.

Zacks Equity Research

Zacks.com featured highlights Lamb Weston, Catalyst Pharmaceuticals and Northeast Community Bank

by Zacks Equity Research

Lamb Weston, Catalyst Pharmaceuticals and Northeast Community Bank have been highlighted in this Screen of The Week article.